AstraZeneca Recommends Shareholders Reject TRC Capital Mini-Tender Bid
18 Ottobre 2021 - 8:50AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Monday that it has recommended shareholders
reject a mini-tender offer from TRC Capital Investment Corporation
for up to two million American Depositary Shares, due to its low
bidding price of up to $115.8 million.
The pharmaceutical company said that the offer was equivalent to
around 0.06% of its issued share capital, at a price of $57.88 per
share in cash.
The offer price is 4.5% lower than the closing price per share
on the Nasdaq Stock Market on Oct. 8, the last trading day before
the tender offer began, the company said.
AstraZeneca said it doesn't in any way recommend or endorse the
offer and recommends that shareholders reject it, given the offer
is below its market price for American Depositary Shares.
Shareholders that have already tendered shares can provide
written notice of withdrawal by Nov. 9.
AstraZeneca said that TRC has made several unsolicited
mini-tender offers for other companies' shares.
It noted that the offers, which are for less than 5% of a
company's outstanding shares, avoid most of the filing, disclosure
and procedural requirements of the U.S. Securities and Exchange
Commission, and therefore don't provide investors with the same
levels of protection provided by larger offers.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
October 18, 2021 02:35 ET (06:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024